We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?
Read MoreHide Full Article
Zoetis Inc. (ZTS - Free Report) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16 before the market opens. The company has consistently beaten earnings expectations. In fact, Zoetis’ earnings surpassed expectations in each of the last four quarters, with an average positive surprise of 12.9%.
In the last reported quarter, the company beat expectations with a positive earnings surprise of 13%. Let's see how things are shaping up for this announcement.
A look at Zoetis’ share price movement in the past one year shows that the stock has outperformed the Zacks classified Medical-Drugs industry. In fact, the stock has gained 42.2% during this period, in comparison to a drop of 4.3% for the industry
Factors to Consider
Concurrent with the third-quarter results, Zoetis updated its outlook for 2016 buoyed by a strong performance through the first nine months of the year, continued strength in the company’s business model and an upbeat view for the rest of the year.
Zoetis now expects earnings in the range of $1.91 to $1.96 per share (old guidance: $1.86–$1.93). It has updated the low end of the revenue guidance for 2016 and now expects revenues of $4.85 billion to $4.9 billion (old guidance: $4.8–$4.9 billion).
The company expects companion animal business to be the main contributor to growth in the fourth-quarter 2016. Zoetis’ companion animal business has been performing well in both the U.S. and international markets, and should continue to do so in the to-be-reported quarter. The business should be driven by higher sales of Apoquel, several new product launches, including Simparica, and market expansion of key product lines. The company is also working on expanding its market share for Apoquel further.
However, the swine business is under pressure in the U.S. due to increased competition. Performance of Zoetis’ livestock business has been disappointing. Poultry business is also declining globally due to market conditions and competitive pressure.
On the fourth-quarter call, investor focus will be on the company’s performance, guidance update for 2017 and its business development plans.
Earnings Whispers
Our proven model does not conclusively show that Zoetis will beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat estimates. Unfortunately, that is not the case here, as you will see below.
Zacks ESP: The Earnings Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, stands at 0.00%. This is because the the Most Accurate estimate and theZ acks Consensus Estimate currently stands at 45 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Zoetis carries a Zacks Rank #4 (Sell) which when combined with a 0.00% ESP makes surprise prediction difficult.
As it is, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Here are other health care stocks that you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +85.7% and a Zacks Rank #3. The company is scheduled to release results on Feb 14.
BioMarin Pharmaceuticals, Inc. (BMRN - Free Report) has an Earnings ESP of +7.5% and a Zacks Rank #3. The company is scheduled to release results on Feb 23.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?
Zoetis Inc. (ZTS - Free Report) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16 before the market opens. The company has consistently beaten earnings expectations. In fact, Zoetis’ earnings surpassed expectations in each of the last four quarters, with an average positive surprise of 12.9%.
In the last reported quarter, the company beat expectations with a positive earnings surprise of 13%. Let's see how things are shaping up for this announcement.
A look at Zoetis’ share price movement in the past one year shows that the stock has outperformed the Zacks classified Medical-Drugs industry. In fact, the stock has gained 42.2% during this period, in comparison to a drop of 4.3% for the industry
Factors to Consider
Concurrent with the third-quarter results, Zoetis updated its outlook for 2016 buoyed by a strong performance through the first nine months of the year, continued strength in the company’s business model and an upbeat view for the rest of the year.
Zoetis now expects earnings in the range of $1.91 to $1.96 per share (old guidance: $1.86–$1.93). It has updated the low end of the revenue guidance for 2016 and now expects revenues of $4.85 billion to $4.9 billion (old guidance: $4.8–$4.9 billion).
The company expects companion animal business to be the main contributor to growth in the fourth-quarter 2016. Zoetis’ companion animal business has been performing well in both the U.S. and international markets, and should continue to do so in the to-be-reported quarter. The business should be driven by higher sales of Apoquel, several new product launches, including Simparica, and market expansion of key product lines. The company is also working on expanding its market share for Apoquel further.
However, the swine business is under pressure in the U.S. due to increased competition. Performance of Zoetis’ livestock business has been disappointing. Poultry business is also declining globally due to market conditions and competitive pressure.
On the fourth-quarter call, investor focus will be on the company’s performance, guidance update for 2017 and its business development plans.
Earnings Whispers
Our proven model does not conclusively show that Zoetis will beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat estimates. Unfortunately, that is not the case here, as you will see below.
Zacks ESP: The Earnings Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, stands at 0.00%. This is because the the Most Accurate estimate and theZ acks Consensus Estimate currently stands at 45 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Zoetis carries a Zacks Rank #4 (Sell) which when combined with a 0.00% ESP makes surprise prediction difficult.
As it is, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. Price and EPS Surprise | Zoetis Inc. Quote
Other Stocks That Warrant a Look
Here are other health care stocks that you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals (PCRX - Free Report) has an Earnings ESP of +20.0% and a Zacks Rank #2 . The company is scheduled to release results on Feb 23. You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +85.7% and a Zacks Rank #3. The company is scheduled to release results on Feb 14.
BioMarin Pharmaceuticals, Inc. (BMRN - Free Report) has an Earnings ESP of +7.5% and a Zacks Rank #3. The company is scheduled to release results on Feb 23.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>